Zimmer Biomet Holdings, Inc. (ZBH) to Issue Quarterly Dividend of $0.24 on April 30th

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) announced a quarterly dividend on Wednesday, February 26th, RTT News reports. Shareholders of record on Monday, March 31st will be given a dividend of 0.24 per share by the medical equipment provider on Wednesday, April 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st.

Zimmer Biomet has a payout ratio of 10.8% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Zimmer Biomet to earn $8.87 per share next year, which means the company should continue to be able to cover its $0.96 annual dividend with an expected future payout ratio of 10.8%.

Zimmer Biomet Stock Down 0.8 %

Shares of NYSE:ZBH opened at $104.03 on Friday. Zimmer Biomet has a 52-week low of $97.69 and a 52-week high of $133.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The business has a fifty day moving average of $105.78 and a two-hundred day moving average of $107.40. The stock has a market cap of $20.71 billion, a P/E ratio of 23.38, a PEG ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the company earned $2.20 earnings per share. On average, research analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. JMP Securities reissued a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Barclays lowered their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Royal Bank of Canada dropped their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Finally, Truist Financial restated a “hold” rating and set a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.